Skip to main content

Table 1 Clinical data of 321 ESRD patients on chronic intermittent hemodialysis

From: Dealing with prognostic signature instability: a strategy illustrated for cardiovascular events in patients with end-stage renal disease

Patients

 

Age (yrs)

66.3 (± 17.3)

Sex (Male (%) / Female (%))

197 (61) / 124 (39)

BMI (kg/m 2)

25.2 (± 5.1)

Dialysis

 

Time on dialysis at inclusion (months)

49 (± 46)

Dialysis treatment duration per week (hrs)

12.7 (± 2.5)

Kt/V (mean of last three

1.27 (± 0.34)

measurements before inclusion)

 

Renal disease

 

Diabetic nephropathy (%)

85 (26)

Glomerulonephritis (%)

75 (23)

Hypertensive/Vascular (%)

48 (15)

ADPKD (%)

26 (8)

Other (%)

46 (14)

Unknown (%)

41 (13)

Clinical chemistry

 

Total cholesterol (mg/dL)

177 (± 43)

Triglycerides (mg/dL)

197 (± 145)

Hemoglobin (g/dL)

11.7 (± 1.5)

CRP (mg/L)

30.5 (± 71.5)

Urea before dialysis (mg/dL)

121 (± 43)

Phosphate (mean of three predialysis

5.6 (± 1.7)

measurements, mg/dL)

 

Total Calcium (corrected for albumin (mmol/L))

2.3 (± 0.3)

Calcium × Phosphate product

50 (± 14)

Parathormon, in patients not

158 (± 201)

parathyroidectomized (pg/ml)

 

Ferritin (ng/mL)

540 (± 332)

Albumin (g/dl)

4.0 (± 0.6)

  1. BMI: Body mass index; ACE-I: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; MI: Myocardial infarction